Novartis AG (NYSE:NVS) to Post FY2026 Earnings of $8.47 Per Share, Zacks Research Forecasts

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research boosted their FY2026 earnings per share (EPS) estimates for Novartis in a report issued on Monday, April 22nd. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of $8.47 for the year, up from their previous forecast of $8.36. The consensus estimate for Novartis’ current full-year earnings is $7.13 per share.

A number of other research firms also recently weighed in on NVS. BMO Capital Markets increased their target price on Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a report on Wednesday. Morgan Stanley initiated coverage on Novartis in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novartis currently has an average rating of “Moderate Buy” and a consensus target price of $115.00.

Novartis Trading Up 1.1 %

Novartis stock opened at $98.35 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.15 and a quick ratio of 0.93. Novartis has a one year low of $92.19 and a one year high of $108.78. The stock has a market capitalization of $201.03 billion, a PE ratio of 13.70, a price-to-earnings-growth ratio of 1.55 and a beta of 0.54. The business’s fifty day moving average is $97.93 and its 200 day moving average is $98.99.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Novartis had a net margin of 29.83% and a return on equity of 29.90%. The business had revenue of $11.42 billion for the quarter, compared to analysts’ expectations of $11.69 billion. During the same period last year, the business earned $1.51 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NVS. IFP Advisors Inc raised its stake in shares of Novartis by 88.1% in the third quarter. IFP Advisors Inc now owns 3,985 shares of the company’s stock worth $406,000 after buying an additional 1,866 shares during the period. Arkadios Wealth Advisors raised its stake in shares of Novartis by 21.4% in the third quarter. Arkadios Wealth Advisors now owns 2,495 shares of the company’s stock worth $254,000 after buying an additional 440 shares during the period. Global Retirement Partners LLC raised its stake in Novartis by 3.4% during the 3rd quarter. Global Retirement Partners LLC now owns 4,544 shares of the company’s stock valued at $437,000 after purchasing an additional 150 shares during the period. HB Wealth Management LLC raised its stake in Novartis by 2.8% during the 3rd quarter. HB Wealth Management LLC now owns 4,677 shares of the company’s stock valued at $476,000 after purchasing an additional 126 shares during the period. Finally, SG Americas Securities LLC raised its stake in Novartis by 75.8% during the 3rd quarter. SG Americas Securities LLC now owns 34,323 shares of the company’s stock valued at $3,496,000 after purchasing an additional 14,797 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Stockholders of record on Friday, March 8th were paid a $3.7772 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a dividend yield of 3.1%. This is an increase from Novartis’s previous annual dividend of $3.47. Novartis’s dividend payout ratio (DPR) is 33.84%.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.